ACLARION, INC. Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price
ACLARION, INC. (ACON) had Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price of $0.82 per share as of 2022-12-31, per its 10-K/A filed 2023-06-12.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2023-06-12
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $0.82.
- 2021-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $0.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price |
|---|---|
| 2022-12-31 | $0.82 10-K/A · filed 2023-06-12 |
| 2021-12-31 | $0.00 10-K/A · filed 2023-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |